Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 7/20 | 0.53 |
| ▸ | PRSS1 | P07477 | 5/20 | 0.53 |
| ▸ | RORC | P51449 | 1/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4843925 | 0.93 | RORC (0.56) | F10PRSS1RORCSLC6A4SLC6A2 | |
| SCHEMBL9925992 | 0.93 | RORC (0.56) | F10PRSS1RORCSLC6A4SLC6A2 | |
| SCHEMBL4843916 | 0.93 | RORC (0.56) | F10PRSS1RORCSLC6A4SLC6A2 | |
| SCHEMBL7888069 | 0.86 | RORC (0.57) | F10PRSS1RORCSLC6A4SLC6A2 | |
| SCHEMBL5110560 | 0.86 | RORC (0.57) | F10PRSS1RORCSLC6A4SLC6A2 | |
| SCHEMBL14498495 | 0.86 | RORC (0.57) | F10PRSS1RORCSLC6A4SLC6A2 | |
| SCHEMBL4661705 | 0.86 | RORC (0.57) | F10PRSS1RORCSLC6A4SLC6A2 | |
| SCHEMBL4661703 | 0.86 | RORC (0.57) | F10PRSS1RORCSLC6A4SLC6A2 | |
| SCHEMBL13809296 | 0.85 | SLC6A4 (0.58) | F10PRSS1RORCSLC6A4SLC6A2 | |
| SCHEMBL1970755 | 0.85 | SLC6A4 (0.58) | F10PRSS1RORCSLC6A4SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7468369-B2 | Sulfonyl pyrrolidines, method for producing the same and their use as drugs | SANOFI-AVENTIS (FR) | 2008-12-23 | — | — | US | disclosed |
| US-20080045540-A1 | SULFONYL PYRROLIDINES, METHOD FOR PRODUCING THE SAME AND THEIR USE AS DRUGS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045540-A1 | SULFONYL PYRROLIDINES, METHOD FOR PRODUCING THE SAME AND THEIR USE AS DRUGS | SLC5A1, SLC5A2, KCNJ1 | F10 3964/4885PRSS1 607/4885RORC 4022/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.